Coherus BioSciences logo

Coherus BioSciences Funding & Investors

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

coherus.com

Total Amount Raised: $770,700,672

Coherus BioSciences Funding Rounds

  • Post Ipo Debt

    $100,000,000

    Post Ipo Debt Investors

    Pharmakon Advisors
  • Post Ipo Debt

    $400,000,000

    Post Ipo Debt Investors

    Armentum Partners
  • Post Ipo Equity

    $50,000,000

    Post Ipo Equity Investors

    Shanghai Junshi Biosciences Co
  • Post Ipo Debt

    $75,000,000

    Post Ipo Debt Investors

    HealthCare Royalty Partners
  • Series C

    $54,700,000

    Series C Investors

    KKR
    Venrock
    Ra Capital Management
    Rock Springs Capital
    Lilly Ventures
    Sofinnova
    Vivo Capital
    Viva Capital Advisors
    F-Prime Capital
    Helix Ventures
    KMG Capital Partners
    Eight Roads Ventures
  • Debt Financing

    $28,000,700

    Debt Financing Investors

    Helix Ventures
  • Series A

    $1,500,000

    Series A Investors

    Helix Ventures
    Medpace
  • Series B

    $61,500,000

    Series B Investors

    Daiichi Sankyo
    Cook Pharmica
    Medpace
    Lilly Ventures
    Helix Ventures
Funding info provided by Diffbot.